Literature DB >> 27374208

Concomitant Adolescent Vaccination in the U.S., 2007-2012.

Jennifer L Moss1, Paul L Reiter2, Noel T Brewer3.   

Abstract

INTRODUCTION: Concomitant (same-day) delivery of two or more vaccines to adolescents is effective, safe, and efficient. Increasing concomitant vaccination could improve coverage for recommended adolescent vaccines, but little is known about who receives vaccines concomitantly.
METHODS: Data came from healthcare provider-verified records on 70,144 adolescents (aged 13-17 years) in the 2008-2012 versions of the National Immunization Survey-Teen who had received at least one dose of tetanus, diphtheria, and acellular pertussis (Tdap) booster; meningococcal conjugate vaccine (MenACWY); or human papillomavirus (HPV) vaccine. Separately for each vaccine, multivariable logistic regression identified adolescent and household correlates of concomitant versus single vaccination, stratified by adolescent sex. Vaccination took place in 2007-2012, data collection in 2008-2012, and data analysis in 2015.
RESULTS: Among vaccinated adolescents, 51%-65% of girls and 25%-53% of boys received two vaccines concomitantly. Concomitant uptake of each vaccine increased over survey years (e.g., 2012 vs 2008: girls' Tdap booster, OR=1.88, 95% CI=1.56, 2.26; boys' Tdap booster, OR=2.62, 95% CI=2.16, 3.16), with the exception of HPV vaccination among boys. Additionally, concomitant vaccination was less common as adolescents got older and in the Northeast (all p<0.05). For MenACWY and HPV vaccine, concomitant uptake was less common for girls whose mothers had higher versus lower education and for boys who lived in metropolitan versus non-metropolitan areas (all p<0.05).
CONCLUSIONS: Missed opportunities for concomitant adolescent vaccination persist, particularly for HPV vaccine. Future interventions targeting groups with low rates of concomitant vaccination could improve population-level coverage with recommended vaccines.
Copyright © 2016 American Journal of Preventive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27374208      PMCID: PMC5067176          DOI: 10.1016/j.amepre.2016.05.013

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  40 in total

1.  Promoting prevention through the Affordable Care Act.

Authors:  Howard K Koh; Kathleen G Sebelius
Journal:  N Engl J Med       Date:  2010-08-25       Impact factor: 91.245

2.  National, State, and Selected Local Area Vaccination Coverage Among Children Aged 19-35 Months - United States, 2014.

Authors:  Holly A Hill; Laurie D Elam-Evans; David Yankey; James A Singleton; Maureen Kolasa
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-08-28       Impact factor: 17.586

3.  Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial.

Authors:  Cosette M Wheeler; Bryan M Harvey; Michael E Pichichero; Michael W Simon; Stephen P Combs; Mark M Blatter; Gary S Marshall; Grégory Catteau; Kurt Dobbelaere; Dominique Descamps; Gary Dubin; Anne Schuind
Journal:  Pediatr Infect Dis J       Date:  2011-12       Impact factor: 2.129

4.  The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil.

Authors:  Richard M Haupt; Heather L Sings
Journal:  J Adolesc Health       Date:  2011-09-09       Impact factor: 5.012

5.  Factors associated with human papillomavirus vaccine-series initiation and healthcare provider recommendation in US adolescent females: 2007 National Survey of Children's Health.

Authors:  May Lau; Hua Lin; Glenn Flores
Journal:  Vaccine       Date:  2012-03-15       Impact factor: 3.641

Review 6.  Systematic review of human papillomavirus vaccine coadministration.

Authors:  Alinea S Noronha; Lauri E Markowitz; Eileen F Dunne
Journal:  Vaccine       Date:  2014-01-08       Impact factor: 3.641

7.  Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area.

Authors:  Noel T Brewer; Sami L Gottlieb; Paul L Reiter; Annie-Laurie McRee; Nicole Liddon; Lauri Markowitz; Jennifer S Smith
Journal:  Sex Transm Dis       Date:  2011-03       Impact factor: 2.830

8.  Adolescent vaccination-coverage levels in the United States: 2006-2009.

Authors:  Shannon Stokley; Amanda Cohn; Christina Dorell; Susan Hariri; David Yankey; Nancy Messonnier; Pascale M Wortley
Journal:  Pediatrics       Date:  2011-11-14       Impact factor: 7.124

Review 9.  Experiences with provider and parental attitudes and practices regarding the administration of multiple injections during infant vaccination visits: lessons for vaccine introduction.

Authors:  Aaron S Wallace; Carsten Mantel; Gill Mayers; Osman Mansoor; Jacqueline S Gindler; Terri B Hyde
Journal:  Vaccine       Date:  2014-08-01       Impact factor: 3.641

10.  National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years--United States, 2014.

Authors:  Sarah Reagan-Steiner; David Yankey; Jenny Jeyarajah; Laurie D Elam-Evans; James A Singleton; C Robinette Curtis; Jessica MacNeil; Lauri E Markowitz; Shannon Stokley
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-07-31       Impact factor: 17.586

View more
  8 in total

1.  Human Papillomavirus Vaccine as an Anticancer Vaccine: Collaborative Efforts to Promote Human Papillomavirus Vaccine in the National Comprehensive Cancer Control Program.

Authors:  Julie S Townsend; C Brooke Steele; Nikki Hayes; Achal Bhatt; Angela R Moore
Journal:  J Womens Health (Larchmt)       Date:  2017-03-06       Impact factor: 2.681

2.  Varicella Vaccination Among US Adolescents: Coverage and Missed Opportunities, 2007-2014.

Authors:  Jessica Leung; Sarah Reagan-Steiner; Adriana Lopez; Jenny Jeyarajah; Mona Marin
Journal:  J Public Health Manag Pract       Date:  2019 May/Jun

3.  Parents' willingness to get human papillomavirus vaccination for their adolescent children at a pharmacy.

Authors:  William A Calo; Melissa B Gilkey; Parth Shah; Macary W Marciniak; Noel T Brewer
Journal:  Prev Med       Date:  2017-02-07       Impact factor: 4.018

4.  Parent-Provider Communication of HPV Vaccine Hesitancy.

Authors:  Laura A Shay; Austin S Baldwin; Andrea C Betts; Emily G Marks; Robin T Higashi; Richard L Street; Donna Persaud; Jasmin A Tiro
Journal:  Pediatrics       Date:  2018-05-15       Impact factor: 7.124

5.  Missed opportunities for human papillomavirus vaccination at office visits during which influenza vaccine was administered: An AAP pediatric research in office settings (PROS) national primary care research network study.

Authors:  Mary Kate Kelly; Robert W Grundmeier; Alisa J Stephens-Shields; Russell Localio; Laura P Shone; Margaret Wright; Jennifer Steffes; Sharon G Humiston; Cynthia Rand; Christina Albertin; Abigail Breck; Dianna E Abney; Greta McFarland; Peter G Szilagyi; Alexander G Fiks
Journal:  Vaccine       Date:  2020-06-12       Impact factor: 3.641

6.  Area-based socioeconomic factors and Human Papillomavirus (HPV) vaccination among teen boys in the United States.

Authors:  Kevin A Henry; Allison L Swiecki-Sikora; Antoinette M Stroup; Echo L Warner; Deanna Kepka
Journal:  BMC Public Health       Date:  2017-07-14       Impact factor: 3.295

7.  Missed Opportunities for Human Papillomavirus Vaccine Initiation in an Insured Adolescent Female Population.

Authors:  Claudia M Espinosa; Gary S Marshall; Charles R Woods; Qianli Ma; Derek Ems; Irene Nsiah; Laura E Happe; Michael J Smith
Journal:  J Pediatric Infect Dis Soc       Date:  2017-11-24       Impact factor: 3.164

8.  Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination.

Authors:  Katia J Bruxvoort; Lei Qian; Jun Wu; Ana Florea; Bradley Ackerson; Lina S Sy; Leticia Vega Daily; Harpreet Takhar; Hung Fu Tseng
Journal:  Open Forum Infect Dis       Date:  2022-02-07       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.